BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30825357)

  • 1. A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome.
    Martini A; Wang J; Brown NM; Cumarasamy S; Sfakianos JP; Rastinehad AR; Haines KG; Wiklund NP; Nair SS; Tewari AK
    BJU Int; 2019 Jul; 124(1):155-162. PubMed ID: 30825357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of Gleason Score 7 With Tertiary Pattern 5 at Radical Prostatectomy.
    Borhan W; Epstein JI
    Urology; 2017 Feb; 100():175-179. PubMed ID: 27810358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
    Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
    Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
    Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
    Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
    Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
    Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.
    Koloff ZB; Hamstra DA; Wei JT; Montgomery JS; Tomlins SA; Wu AJ; Morgan TM; Siddiqui J; Paich K; Chinnaiyan AM; Feng FY; Weizer AZ; Kunju LP; Hollenbeck BK; Miller DC; Palapattu GS; Mehra R
    Asian J Urol; 2015 Jan; 2(1):53-58. PubMed ID: 29264120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential.
    Klein EA; Santiago-Jiménez M; Yousefi K; Robbins BA; Schaeffer EM; Trock BJ; Tosoian J; Haddad Z; Ra S; Karnes RJ; Jenkins RB; Cheville JC; Den RB; Dicker AP; Davicioni E; Freedland SJ; Ross AE
    J Urol; 2017 Jan; 197(1):122-128. PubMed ID: 27569435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Expression of Connective Tissue Genes and Prostate Cancer Growth and Progression.
    Treacy PJ; Martini A; Falagario UG; Ratnani P; Wajswol E; Beksac AT; Wiklund P; Nair S; Kyprianou N; Durand M; Tewari AK
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
    Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
    Doshi C; Vacchio M; Attwood K; Murekeyisoni C; Mehedint DC; Badkhshan S; Azabdaftari G; Sule N; Guru KA; Mohler JL; Kauffman EC
    Prostate; 2016 Jun; 76(8):715-21. PubMed ID: 26880312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.